Royalty Pharma Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Royalty Pharma stock has a consensus rating of "Buy" and an average price target of $72. The average 1-year stock price forecast is 3.88% higher than the current stock price, while the lowest is $66 (-4.78%) and the highest is $78 (+12.54%).

Price Target: $72 (+3.88%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$66	$72	$74	$78
Change	-4.78%	+3.88%	+6.77%	+12.54%

Analyst Ratings

The average analyst rating for Royalty Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26	Nov '26
Strong Buy	6	6	5	5	5	5
Buy	2	2	2	2	2	2
Hold	2	2	1	1	1	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	10	8	8	8	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Terence Flynn Morgan Stanley	Morgan Stanley	Buy Reiterates $67 → $75	Buy	Reiterates	$67 → $75	+8.21%	Nov 5, 2026
Geoff Meacham Citi	Citi	Buy Maintains $70 → $78	Buy	Maintains	$70 → $78	+12.54%	Nov 5, 2026
Chris Schott J.P. Morgan	J.P. Morgan	Buy Maintains $62 → $74	Buy	Maintains	$62 → $74	+6.77%	Nov 4, 2026
Jason Gerberry Bank of America Securities	Bank of America Securities	Buy Maintains $63	Buy	Maintains	$63	-9.10%	Oct 9, 2026
Michael Nedelcovych TD Cowen	TD Cowen	Buy Reiterates $65 → $68	Buy	Reiterates	$65 → $68	-1.89%	Sep 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.55B

from 2.38B

49.27%

from 2.38B

Revenue Next Year

3.87B

from 3.55B

9.11%

from 3.55B

EPS This Year

5.39

from 4.83

11.66%

from 4.83

EPS Next Year

5.91

from 5.39

9.61%

from 5.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.29B	2.24B	2.35B	2.26B	2.38B	3.55B
Revenue Growth	7.87%	-2.28%	5.24%	-3.86%	5.06%	49.27%
Operating Income	1.43B	922.89M	1.49B	1.29B	1.56B	2.75B
Net Income	619.73M	42.83M	1.13B	858.98M	770.95M	1.47B
EPS	-	-	-	-	4.83	5.39
EPS Growth	-	-	-	-	17.00%	11.66%
Forward PE	13.00	10.32	7.47	6.10	7.70	12.85
Dividend / Share	0.68	0.76	0.80	0.84	0.88	1.04
Dividend Growth	126.67%	11.77%	5.26%	5.00%	4.76%	17.84%
Free Cash Flow	-	-	-	-	2.72B	3.12B
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	3.6B
Avg	3.5B
Low	3.5B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	50.6%
Avg	49.3%
Low	47.8%

EPS Forecast

Chart

EPS	2026	2027	2028
High	5.49
Avg	5.39
Low	5.31

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	13.6%
Avg	11.7%
Low	9.9%